Sermorelin vs Tesamorelin

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

Sermorelin: CTesamorelin: A

Attribute	Sermorelin	Tesamorelin
Category	Growth Hormone Secretagogue	Growth Hormone Secretagogue
Evidence Rating	C — Phase I–II Clinical Trials	A — FDA Approved
Clinical Status	Previously FDA-approved (Geref, discontinued); now used off-label via compounding	FDA-approved (Egrifta SV 2019, Egrifta WR March 2025) for HIV-associated lipodystrophy
Mechanism	Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland, stimulating both transcription of the HGH gene and pulsatile release of endogenous growth hormone. The released HGH increases protein synthesis, fat breakdown (lipolysis), and tissue repair across multip...	Tesamorelin binds to and stimulates human GRF (growth hormone-releasing factor) receptors on the anterior pituitary with similar potency as endogenous GRF, stimulating synthesis and release of endogenous growth hormone. This increases IGF-1 and IGFBP-3 levels, leading to increased lipolysis and redu...
Half-Life	~10–20 minutes	~26–38 minutes
Bioavailability	—	—
Molecular Weight	~3357.9 g/mol	~5135.9 g/mol
WADA Status	Prohibited	Prohibited
Dosing	100–300 mcg/day SC, Once daily (typically before bed) (Subcutaneous)	2 mg/day SC (FDA-approved dose), Once daily (Subcutaneous)
Key Use Cases	Anti-Aging Body Composition Sleep	Body Composition
Safety Concerns	Generally well-tolerated in clinical studies; safety data from published trials supports good tolerability profile Common: injection site reactions (redness, swelling, mild pain — typically resolve within days) Systemic: headaches, nausea, dizziness, facial flushing, drowsiness (mild, transient, usually in initial weeks as the body adjusts)	Common: injection site reactions (17%), arthralgia (13%), myalgia (6%), peripheral edema (6%) Headache, nausea, and flu-like symptoms reported May increase blood glucose -- monitoring recommended in diabetics
Contraindications	Active malignancy or active cancer (GH promotes cell proliferation) Pregnancy and breastfeeding Pituitary disorders or prior pituitary surgery Uncontrolled diabetes, severe sleep apnea, or untreated hypertension	Pregnancy (Category X -- absolute contraindication) Active cancer or history of any tumor (benign or malignant) Pituitary gland disorder, tumor, or history of pituitary surgery History of head injury or radiation treatment to the head
Regulatory (US)	Previously FDA-approved (Geref) for pediatric GH deficiency; voluntarily discontinued by manufacturer for commercial reasons. FDA confirmed in 2013 it was not withdrawn for safety. Available via compounding pharmacies. WADA-banned.	FDA-approved: Egrifta SV (Oct 2019) and Egrifta WR (March 2025) for HIV-associated lipodystrophy. Prescription only.

Shop Sermorelin

View Sermorelin Product

Shop Tesamorelin

View Tesamorelin Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All Comparisons Browse Catalog

Sermorelin vs Tesamorelin

Explore MoreComparisons

Your Cart

Explore More
Comparisons